PDF(Pubmed)
Abstract：
UNASSIGNED: The guidelines\' recommendations for anticoagulation in cancer patients with catheter-related thrombosis are unclear. The aim of this systematic review was to assess anticoagulation management in cancer patients with catheter-related thrombosis (CRT) based on previously published studies.
UNASSIGNED: As of June 10, 2023,we searched databases including PubMed, Embase, and Cochrane and included 11 observational studies that met the criteria. We evaluated 770 adults with active cancer and objectively confirmed patients with CRT who were using drugs including warfarin, LMWH, and new oral anticoagulants as antithrombotic therapy.
UNASSIGNED: We extracted outcome data, including thrombosis recurrence, catheter dysfunction, major bleeding, and death, and performed a meta-analysis.
UNASSIGNED: In this study we found that the risk of VTE recurrence was higher with rivaroxaban, the risk of bleeding and death appeared to be greater with warfarin, and although the risk of catheter dysfunction due to LMWH is a concern, it is still a more reasonable option for cancer patients with catheter-related thrombosis.
UNASSIGNED: http://www.clinicaltrials.gov, identifier (CRD42022367979).
UNASSIGNED: As of June 10, 2023,we searched databases including PubMed, Embase, and Cochrane and included 11 observational studies that met the criteria. We evaluated 770 adults with active cancer and objectively confirmed patients with CRT who were using drugs including warfarin, LMWH, and new oral anticoagulants as antithrombotic therapy.
UNASSIGNED: We extracted outcome data, including thrombosis recurrence, catheter dysfunction, major bleeding, and death, and performed a meta-analysis.
UNASSIGNED: In this study we found that the risk of VTE recurrence was higher with rivaroxaban, the risk of bleeding and death appeared to be greater with warfarin, and although the risk of catheter dysfunction due to LMWH is a concern, it is still a more reasonable option for cancer patients with catheter-related thrombosis.
UNASSIGNED: http://www.clinicaltrials.gov, identifier (CRD42022367979).
摘要：
■关于导管相关性血栓形成的癌症患者抗凝治疗的指南建议尚不清楚。本系统综述的目的是根据先前发表的研究评估导管相关性血栓形成（CRT）的癌症患者的抗凝管理。
■截至2023年6月10日，我们搜索了包括PubMed在内的数据库，Embase,和Cochrane，包括11项符合标准的观察性研究。我们评估了770名患有活动性癌症的成年人，并客观证实了使用包括华法林在内的药物的CRT患者，LMWH,和新的口服抗凝剂作为抗血栓治疗。
■我们提取了结果数据，包括血栓复发,导管功能障碍,大出血,和死亡,并进行了荟萃分析。
■在这项研究中，我们发现利伐沙班的VTE复发风险更高，华法林的出血和死亡风险似乎更大，尽管LMWH引起的导管功能障碍的风险令人担忧，对于有导管相关性血栓形成的癌症患者，它仍然是一个更合理的选择。
■http://www.clinicaltrials.gov,标识符(CRD42022367979)。
■截至2023年6月10日，我们搜索了包括PubMed在内的数据库，Embase,和Cochrane，包括11项符合标准的观察性研究。我们评估了770名患有活动性癌症的成年人，并客观证实了使用包括华法林在内的药物的CRT患者，LMWH,和新的口服抗凝剂作为抗血栓治疗。
■我们提取了结果数据，包括血栓复发,导管功能障碍,大出血,和死亡,并进行了荟萃分析。
■在这项研究中，我们发现利伐沙班的VTE复发风险更高，华法林的出血和死亡风险似乎更大，尽管LMWH引起的导管功能障碍的风险令人担忧，对于有导管相关性血栓形成的癌症患者，它仍然是一个更合理的选择。
■http://www.clinicaltrials.gov,标识符(CRD42022367979)。
